Top Story

FDA expands approval of Imbruvica to treat Waldenström's macroglobulinemia

January 29, 2015

The FDA today announced the expanded approval of ibrutinib for the treatment of Waldenström’s macroglobulinemia, a rare form of non-Hodgkin’s lymphoma. The drug also received breakthrough therapy designation for this use.

Ibrutinib (Imbruvica, Pharmacyclics and Janssen Biotech) blocks the enzyme that allows abnormal B cells in Waldenström’s macroglobulinemia to grow and divide.

In the Journals

Biomarkers predicted severity of GVHD after allogenic HSCT

January 29, 2015
A prognostic score based on the concentration of biomarkers guided risk-adapted therapy at the onset of graft-versus-host disease following allogeneic hematopoietic stem…
Jae Cheol Lee, MD, PhD In the Journals

Pemetrexed benefited lung cancer patients with ALK mutations

January 29, 2015
Patients with lung adenocarcinoma who have anaplastic lymphoma kinase gene mutations derived greater benefit from pemetrexed-based therapy than those without the…
Srdan Verstovsek In the Journals

Ruxolitinib superior to standard therapy for polycythemia vera

January 28, 2015
Patients with polycythemia vera who were resistant to or intolerant of hydroxyurea therapy demonstrated better controlled hematocrit levels, reduced spleen volume and…
Gregory Armstrong, MD In the Journals

Variation in risk for late mortality among pediatric cancer survivors can persist up to 20 years post-diagnosis

January 28, 2015
Although all survivors of pediatric cancer face increased risk for death, the risk is reduced as survivors age through childhood and young adulthood, according to study…
More News Headlines »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Genome editing demonstrated wide application for blood disorders

Genome editing demonstrated wide application for blood disorders

January 4, 2015
SAN FRANCISCO — Ralph Green, MD, PhD, FRCPath, medical director of the UC Davis Health System Medical…
More »
CME
New Advances, New Options: Evaluating the Changing Landscape of Hemophilia

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »
morganatic-roan